Uncategorized

Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms

Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms

Published

on

The industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile, Pfizer, Merck and others release second quarter earnings, with some disclosing pipeline discontinuations and cost-cutting measures. Finally, all eyes turn to the FDA in the wake of heated advisory committee meetings for Capricor Therapeutics and Replimune.​ ​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version